Online Nursing Practice Test about Pharmacology (16-20)

16. The client with liver cirrhosis has an ammonia level of 80 mcg/dl. Which of the following medications does the nurse anticipate to be ordered for the client?

a) dulcolax
b) metamucil
c) lactulose
d) senokot

17. Which of the following indicates effectiveness of Spirolactone, in the client with liver cirrhosis?

a) increase in weight
b) decrease in abdominal girth
c) increase in serum potassium level
d) decrease in jaundice

18. Which of the following is a contraindication to influenza vaccine?

a) chronic illness
b) allergy to eggs
c) diabetes mellitus
d) chronic obstructive pulmonary disease

19. Sulfasalazine (Azulfidine) is prescribed for a client with a diagnosis of ulcerative colitis. A nurse instructs the client about the medication. Which statement when made by the client indicates that he understands the teaching about the medication?

a) I should avoid exposure to sunlight
b) this medication will cause constipation
c) this medication should be taken with meals
d) this medication should be taken as prescribed

20. Which of the following assessment data when made by the nurse indicates effectiveness of lithium?

a) the client paces along the hallway during the night
b) the client refuses to eat in the dining room
c) the client is able to attend the conference on time
d) the client washes his hands less frequently



ANSWERS AND RATIONALE

16) C
- lactulose blocks ammonia formation. The normal serum ammonia level is 35-65 mcg/dL.

17) B
- spirolactone is a diuretic. It increases urine output, and reduces ascites in clients with liver cirrhosis. Therefore, decrease in abdominal girth indicates resolution of ascites.

18) B
- allergy to eggs is contraindication to influenza vaccine.

19) A
- sulfonamides cause photosensitivity. The client should avoid exposure to sunlight

20) C
- lithium is antimanic. Improved attention span and concentration ability indicate that the manic behavior is resolving. These indicate effectiveness of lithium.



Related Topics:

0 comments: